A pipeline of transformational medicines with the development program driven by our team of experts.
Our CinCo’s
Metabolic

    |
  • Pre-clinical
    • |
  • Phase 1
    • |
  • Phase 2
    • |
  • Phase 3
    • |

    |
  • Pre-clinical
    • |
  • Phase 1
    • |
  • Phase 2
    • |
  • Phase 3
    • |

CIN-109
GDF-15 Analog
CIN-110
PYY 3-36 Analog
CIN-209
GDF-15 / GLP-1 - Dual Agonist
CIN-210
PYY 3-36 / GLP-1 - Dual Agonist

CIN-109, CIN-110, CIN-209 and CIN-210 are series of mono and combination therapies for the treatment of obesity.
Read more

Gastrointestinal

    |
  • Pre-clinical
    • |
  • Phase 1
    • |
  • Phase 2
    • |
  • Phase 3
    • |

CIN-102
Gastroparesis

Deudomperidone (CIN-102) is a Dopamine 2/3 antagonist with prokinetic and antiemetic effects.

Read more

    |
  • Pre-clinical
    • |
  • Phase 1
    • |
  • Phase 2
    • |
  • Phase 3
    • |

CIN-103
IBS-D
CIN-103 is a novel formulation of phloroglucinol modified to enhance the pharmacokinetic properties to sustain the therapeutic exposure for patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Read more
Oncology

    |
  • Pre-clinical
    • |
  • Phase 1
    • |
  • Phase 2
    • |
  • Phase 3
    • |

CIN-108
Oncology
CIN-108 is a small molecule inhibiting defective in cullin neddylation 1 (DCN1) from binding in the pocket where it is necessary to promote neddylation and interfere with the progression of multiple solid tumors.
Read more
Our CINergy Partnerships

    |
  • Pre-clinical
    • |
  • Phase 1
    • |
  • Phase 2
    • |
  • Phase 3
    • |

TTP399
Type 1 Diabetes

An oral small molecule, adjunct therapy to insulin in patients with type 1 diabetes (T1D).

Read more

    |
  • Pre-clinical
    • |
  • Phase 1
    • |
  • Phase 2
    • |
  • Phase 3
    • |

Neuro-
degenerative

Retromer Therapeutics is developing novel medicines to treat neurodegenerative diseases.
Read more

844-531-1834 | [email protected]
© 2024 CinRx Pharma. All Rights Reserved.

SITE PAGES

CINRX IN THE NEWS

FOLLOW US

Linkedin-in
844-531-1834 | [email protected]
Linkedin-in

© 2023 CinRx Pharma. All Rights Reserved.

INVESTOR INQUIRIES

CAREER INQUIRIES

GENERAL INQUIRIES